Articles tagged "Immunosuppression"

2022 American Transplant Congress
Prevalence of Mycophenolate Mofetil (MMF) Discontinuation and Outcomes in Pediatric Kidney Transplants (PKTX): A PNRC Study
A. Moudgil¹, K. Sgambat¹, E. Benoit², A. Jain³, M. Seifert⁴, C. Katsoufis⁵, L. Harshman⁶, A. Mansuri⁷, M. Somers⁸
¹Nephrology, Children's National Med. Ctr., Washington, DC, ²Nephrology, Boston's Children's Hospital, Boston, MA, ³Nephrology, Wayne State University, Troy, DC, ⁴Nephrology, The University of Alabama, Birmingham, AL, ⁵Nephrology, Holtz Children's Hospital, Miami, FL, ⁶Nephrology, University of Iowa, Iowa City, IA, ⁷Nephrology, Children's Hospital of Georgia, Augusta, GA, ⁸Nephrology, Boston Children's Hospital, Boston, MA
*Purpose: MMF is discontinued in PKTX for various reasons. In this Pediatric Nephrology Research Consortium (PNRC) study, we determined prevalence and reasons for MMF discontinuation…
2022 American Transplant Congress
Comparison of Immediate-Release Tacrolimus to Envarsus XR on the Development of Donor Specific Antibodies in Kidney Transplant Recipients
R. A. Arora, C. Kane, K. Lang, M. Kapugi, C. D'Agostino, K. Cunningham, S. H. Park
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Major causes of de novo development of donor specific antibodies (DSA) after kidney transplant include medication noncompliance and immunosuppression minimization or elimination that may…
2022 American Transplant Congress
Humoral and Cellular Immune Response to a Third Dose Of SARS-CoV-2 Vaccine in Kidney Transplant Recipients on Belatacept
J. Mitchell¹, J. Alejo¹, T. P. Chiang¹, J. N. Blankson¹, A. H. Karaba¹, B. Woldemeskel¹, C. Garliss¹, A. Chang¹, A. Abedon¹, R. K. Avery¹, A. Tobian¹, A. B. Massie¹, J. Garonzik-Wang², D. L. Segev¹, W. Werbel¹
¹Johns Hopkins University, Baltimore, MD, ²University of Wisconsin, Madison, WI
*Purpose: Kidney transplant recipients taking belatacept (KTR-B) have poor immune response to two-dose SARS-CoV-2 vaccination. We sought to characterize the impact of an additional vaccine…
2022 American Transplant Congress
Incidence and Outcomes of CMV Infection in Pancreas Transplant with Thymoglobulin Induction: A Single Center Experience
W. Abusalah, A. Yadav
Thomas Jefferson University Hospital, Philadelphia, PA
*Purpose: CMV infection is a major infectious complication in pancreas transplant recipients (PTR). Incidence of CMV viremia in PTR with thymoglobulin induction and it's effect…
2022 American Transplant Congress
Efficacy and Safety of a Delayed Graft Function Protocol in Kidney Transplant Recipients
V. Vu¹, S. Bhayana², H. Sweiss¹, N. Castro¹, R. Hall¹, J. Nelson¹
¹University Health, San Antonio, TX, ²University of Texas Health Science Center at San Antonio, San Antonio, TX
*Purpose: To evaluate the efficacy and safety of a protocol increasing the net state of immunosuppression for adult kidney transplant recipients (KTR) with delayed graft…
2022 American Transplant Congress
A Single Center Experience of Simultaneous Heart-Kidney Transplantation
A. Samra¹, A. Mattoo²
¹Nephrology, New York University Langone Transplant Institute, New York, NY, ²New York University Langone Transplant Institute, New York, NY
*Purpose: Currently there are no UNOS guidelines regarding the selection criteria required for simultaneous heart-kidney transplant recipients (SHKT). As of 2018 our center has begun…
2022 American Transplant Congress
Five-Year Follow-Up from a Prospective, Randomized Trial of Belatacept-Based, CNI Free/Early Steroid Withdrawal Regimens
H. Hames¹, A. R. Shields¹, E. Yanqui¹, A. Christianson¹, J. Kremer², A. Govil¹, E. S. Woodle¹, R. R. Alloway¹
¹University of Cincinnati, Cincinnati, OH, ²Christ Hospital, Cincinnati, OH
*Purpose: A prospective, randomized, multi-center trial designed to compare two belatacept (BELA)-based, calcineurin inhibitor-free (CNI), early corticosteroid withdrawal (ESW) regimens with a tacrolimus (TAC)-based ESW…
2022 American Transplant Congress
Synergistic Effect of CXCR5⁺CD8⁺ T_Ab-supp Cell Adoptive Cell Therapy and mTOR Inhibition (but Not Calcineurin Inhibition) in Suppressing Alloantibody Following Kidney Transplant in Mice
J. L. Han¹, J. M. Zimmerer¹, Q. Zeng², S. Chaudhari¹, C. K. Breuer², G. L. Bumgardner¹
¹Dept. of Surgery, The Ohio State University, Columbus, OH, ²Center for Regen. Med., The Research Institute at Nationwide Children's Hospital, Columbus, OH
*Purpose: We have reported that CXCR5+CD8+TAb-supp cells mediate suppression of alloantibody (alloAb) production and prolong graft survival in both hepatocellular and kidney transplant (KTx) mouse…
2022 American Transplant Congress
Kidney Transplant Recipients with Diabetic Mellitus Demand Larger Doses of Mycophenolate Mofetil
D. Takamoto, H. Sasaki, S. Harada, Y. Takada, H. Harada, T. Tsujimoto
Kidney transplant surgery and Urology, Sapporo City General Hospital, Sapporo, Japan
*Purpose: To monitor blood concentration of immunosuppressants, therapeutic drug monitoring (TDM) is required at any point after kidney transplantation (KT) to prevent kidney graft from…
2022 American Transplant Congress
Association Between De Novo Donor Specific Antibody and Tacrolimus Trough Levels in Long Term Follow Up Renal Transplantation
N. Fujiyama¹, M. Saito², R. Yamamoto², R. Sagehashi², T. Saito², Y. Aoyama², K. Numakura², T. Habuchi², S. Satoh¹
¹Center for Kidney Disease and Transplantation, Akita University Hospital, Akita, Japan, ²Department of Urology, Akita University Graduate School of Medicine, Akita, Japan
*Purpose: In this study, we aimed to identify the risk factors contributing to the development of donor-specific anti-HLA antibody (DSA) during long-term follow-up of patients…